PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of wjgLink to Publisher's site
 
World J Gastroenterol. 2010 April 14; 16(14): 1683–1687.
Published online 2010 April 14. doi:  10.3748/wjg.v16.i14.1683
PMCID: PMC2852814

Controlling postoperative ileus by vagal activation

Abstract

Postoperative ileus is a frequently occurring surgical complication, leading to increased morbidity and hospital stay. Abdominal surgical interventions are known to result in a protracted cessation of bowel movement. Activation of inhibitory neural pathways by nociceptive stimuli leads to an inhibition of propulsive activity, which resolves shortly after closure of the abdomen. The subsequent formation of an inflammatory infiltrate in the muscular layers of the intestine results in a more prolonged phase of ileus. Over the last decade, clinical strategies focusing on reduction of surgical stress and promoting postoperative recovery have improved the course of postoperative ileus. Additionally, recent experimental evidence implicated antiinflammatory interventions, such as vagal stimulation, as potential targets to treat postoperative ileus and reduce the period of intestinal hypomotility. Activation of nicotinic receptors on inflammatory cells by vagal input attenuates inflammation and promotes gastrointestinal motility in experimental models of ileus. A novel physiological intervention to activate this neuroimmune pathway is enteral administration of lipid-rich nutrition. Perioperative administration of lipid-rich nutrition reduced manipulation-induced local inflammation of the intestine and accelerated recovery of bowel movement. The application of safe and easy to use antiinflammatory interventions, together with the current multimodal approach, could reduce postoperative ileus to an absolute minimum and shorten hospital stay.

Keywords: Postoperative ileus, Inflammation, Vagus, Nutritional antiinflammatory pathway

INTRODUCTION

Postoperative ileus is a common pathological condition in the surgical ward and presents as an inability to tolerate enteral nutrition, nausea, abdominal distension, and lack of flatus and defecation. Although all surgical patients are at risk of developing postoperative ileus, the condition is mostly observed after abdominal surgery with manipulation of the gastrointestinal tract[1]. Cessation of bowel movement and delayed gastric emptying, which can be up to 5 d after colorectal surgery, results in increased morbidity and a prolonged hospital stay[2-4]. The duration of postoperative ileus has a major financial impact, adding an average of 6.300 US$ to hospital costs per patient who develops ileus[5]. The additional health care costs in the US have been estimated to be 1.5 billion US$ annually[6]. Increased insight into the pathophysiology and discovery of novel treatment options could diminish the length of postoperative ileus, decrease patient morbidity, and reduce hospital costs.

PATHOPHYSIOLOGY OF POSTOPERATIVE ILEUS

The pathophysiology underlying postoperative ileus is complex and multifactorial, consisting of endogenous and pharmacological characteristics. Recent experimental studies have demonstrated that the pathogenesis of the endogenous component of postoperative ileus can be grossly divided in two distinct phases[1]. The first phase, or neural phase, results from activation of mechanoreceptors and nociceptors by stimuli, such as incision of the skin and, more importantly, by direct manipulation of the intestine[7]. Activation of these receptors initiates a neural reflex, which is dependent on release of mediators, such as α-calcitonin gene-related peptide and substance P, which inhibit gastrointestinal motility and result in generalized intestinal hypomotility[8-10]. The neural phase of postoperative ileus lasts minutes to hours and resolves after closure of the wound when the noxious stimuli have ceased[9,11,12]. The motility of the colon in particular depends heavily on input from the autonomic nervous system, which might explain colonic susceptibility to isolated and prolonged ileus[13].

The second, more protracted, inflammatory phase is caused by formation of an inflammatory infiltrate in the muscular layers of the intestine[7,14,15]. Manipulation of the intestine initiates an inflammatory cascade starting with activation and degranulation of mast cells[16-18]. Subsequently, resident macrophages are activated either via mast cell-derived mediators or by luminal antigens[17,19,20]. These activated macrophages produce cytokines and chemokines, which attract neutrophils to the muscular layer of the intestine. Invaded neutrophils directly impair intestinal smooth muscle cell contractility via release of nitric oxide and prostaglandins[21,22]. The formation of an inflammatory infiltrate not only impairs motility in the manipulated areas, but also leads to generalized hypomotility of the gastrointestinal tract via activation of inhibitory adrenergic neural pathways. There is emerging evidence that inflammation also plays a vital role in postoperative ileus in humans, therefore a major focus of current research has been directed at the development of antiinflammatory treatments[18,23,24]. In experimental models of intestinal manipulation, it was demonstrated that administration of antiinflammatory agents, such as mast cell stabilizers[17], non-steroidal antiinflammatory drugs[25,26], and interleukin (IL)-10[27], prevent development of postoperative ileus. In addition, it was recently shown in patients undergoing major abdominal surgery that an intervention with the mast cell stabilizer, Ketotifen, reduced gastroparesis[24].

CLINICAL STRATEGIES TO TREAT POSTOPERATIVE ILEUS

A number of strategies for preventing postoperative ileus are combined in the so-called fast-track program. The goals of fast-track surgery are reduction of perioperative surgical stress and promotion of postoperative recovery. Adequate pain relief, minimal invasive surgery and early enteral nutrition are important to achieve these goals[28]. Adequate pain relief can attenuate postoperative ileus in two important ways. First, intraoperative spinal anesthesia and postoperative epidural analgesia with local anesthetics during abdominal surgery reduce the neural phase of ileus by interruption of neural transmission. Second, local anesthetic interventions minimize the use of opioid-derivatives[29,30]. Both endogenous opioids, released in response to noxious stimuli, and exogenous opioids are notorious for their inhibitory effect on gastrointestinal motility, thereby aggravating postoperative ileus[31]. Blocking the μ-opioid receptor with Alvimopan, a selective, peripherally active antagonist, has been demonstrated to accelerate recovery of bowel function and decrease hospital stay, without affecting the analgesic effects of opioids[32,33]. In addition, non-steroidal antiinflammatory drugs seem promising for their opioid-sparing and antiinflammatory effects[26,34]. However, caution should be taken as the use of cyclo-oxygenase-2 inhibitors after colonic surgery has been associated with increased anastomotic leakage[35].

Surgical trauma and direct manipulation of the intestine are major factors in the occurrence of postoperative ileus. The degree of gastrointestinal hypomotility correlates with the degree of manipulation and intestinal inflammation[19]. The introduction of minimally invasive techniques, such as laparoscopy, significantly reduced the duration of postoperative ileus and length of hospital stay[36]. This improvement is probably due to minimization of trauma, resulting in less pain and a diminished release of neurotransmitters and inflammatory mediators[18,28,37].

Finally, enteral nutrition is found to be essential for enhanced recovery after surgery. Ingestion of nutrients elicits various reflexes and releases several neuropeptides that promote gastrointestinal motility[38,39]. Traditionally however, a nil-by-mouth regime is often enforced starting from several hours before surgery until days postoperatively. Recent studies have demonstrated that early enteral nutrition is safe and well tolerated after abdominal surgery. In addition, early enteral nutrition reduces postoperative ileus and length of hospital stay[40,41]. Unfortunately, studies investigating the effect of early enteral nutrition on postoperative ileus remain difficult to interpret, as the studies often lack essential information on the type of analgesia that was used[2]. Enteral nutrition is a promising intervention to treat ileus; however, future well-designed studies are needed to evaluate the effect of early enteral nutrition on intestinal motility. When implementing early enteral nutrition routinely, caution should be taken, as there is a small chance that enteral nutrition could lead to intestinal ischemia in the circulatory compromised patient[42,43].

The implementation of fast-track regimes in the surgical field has improved the course of postoperative ileus. However, despite these efforts, it still remains an important clinical challenge. Inhibition of the inflammatory phase, by targeting the cellular and molecular changes underlying postoperative ileus is another focus of treatment.

EXPERIMENTAL STRATEGIES TO CONTROL POSTOPERATIVE ILEUS

The inflammatory phase dominates the course of postoperative ileus. Novel experimental interventions aimed at preventing the activation of inflammatory cells, such as administration carbon monoxide[44,45], pretreatment with blocking antibodies to intracellular adhesion molecule-1 and lymphocyte function-associated antigen-1[7,46], inactivating macrophages[47], and preventing mast cell activation[17], have displayed promising results in reducing gastrointestinal hypomotility. Borovikova et al[48] described a novel approach for modulating the inflammatory response; electrical stimulation of the vagus nerve attenuates systemic inflammation in a murine endotoxin model. Stimulation of the vagus nerve modulates inflammation via release of acetylcholine that binds to nicotinic receptors on inflammatory cells, hence the term “cholinergic anti-inflammatory pathway”[49,50]. In addition, the vagus nerve has recently been identified as an important modulator of intestinal health; loss of vagal integrity aggravates intestinal inflammation and augments loss of gut barrier function[51,52].

In a murine model of intestinal manipulation, electrical stimulation of the vagus nerve ameliorates postoperative gastrointestinal hypomotility via inhibition of local intestinal inflammation. Vagal stimulation activates the α7 nicotinic acetylcholine receptor on intestinal macrophages and attenuates release of pro-inflammatory cytokines via the Jak2-Stat3 signaling pathway[53]. Furthermore, administration of the selective α-7 receptor agonist, AR-R17779, prevented postoperative ileus in mice[54]. Although very effective in preventing postoperative ileus in animal models, caution should be taken when implementing electric vagus stimulation and pharmacologic interventions in patients. Electrical stimulation remains an invasive procedure, while pharmacologic stimulation of nicotinic receptors might cause unwanted stimulation of different cell types and organs[55,56].

A more physiological way to activate the vagal antiinflammatory pathway is by administration of enteral nutrition enriched with lipids. Administration of lipid-rich nutrition prior to, or following, hemorrhagic shock attenuates systemic inflammation and preserves intestinal integrity[57,58]. These positive effects of lipid-rich nutrition on gut barrier function and systemic inflammation are specific for the amount of lipids in the nutrition, as a low-lipid control feeding did not exert these protective effects. The enteral presence of lipids activates the autonomic nervous system via cholecystokinin (CCK) receptors. Subsequently, inflammation is inhibited through activation of nicotinic receptors on inflammatory cells via the efferent vagus[59]. Enteral administration of lipid-rich nutrition was demonstrated to reduce postoperative ileus in a rodent model of intestinal manipulation[16]. Enteral nutrition enriched with lipids prevented degranulation of mast cells, inhibited release of macrophage-derived tumor necrosis factor-α and IL-6, and prevented influx of neutrophils into the intestinal muscularis to a greater extent than the control, low-lipid, nutrition. More importantly, the beneficial effect of lipid-rich nutrition on manipulation-induced local inflammation promoted gastrointestinal transit in a CCK-receptor-dependent manner[16]. These findings indicate that lipid-rich nutrition reduces postoperative ileus via activation of the nutritional antiinflammatory pathway. Luminal lipids are known to activate the autonomic nervous system via CCK-mediated stimulation of peripheral CCK-1 receptors on afferent vagal fibers, resulting in several regulatory digestive functions, such as satiety[60]. Therefore, the antiinflammatory potential of lipid-rich enteral nutrition could rely on activation of a nutritional CCK-dependent vagovagal reflex.

Interestingly, sham feeding is another physiological technique that activates the cephalic vagal axis by mimicking food intake, thereby stimulating bowel motility[38,39]. Furthermore, activation of the cephalic phase elicits digestive functions via vagovagal cholinergic reflexes[61]. Sham feeding by chewing gum has been shown to improve bowel movement and reduce time to first flatus and first defecation after open gastrointestinal surgery, and demonstrates a trend towards a reduced hospital stay[62,63]. However, the exact mode of action remains to be investigated.

CONCLUSION

Surgical interventions, and abdominal surgery in particular, are frequently accompanied by the occurrence of postoperative ileus. Postoperative ileus is a multifactorial surgical complication that requires a multifactorial treatment approach. Minimal invasive surgery to reduce surgical stress, epidural analgesia to block inhibitory reflexes, minimizing opioid use, and attenuation of intestinal inflammation by antiinflammatory interventions should reduce postoperative ileus to a minimum. The development of safe and easy-to-use treatments to prevent intestinal inflammation will play a key role in controlling postoperative ileus and deserves further investigation. Stimulation of the vagal antiinflammatory pathway, by interventions such as enteral administration of lipids, is one of the promising interventions contributing to a further reduction of postoperative ileus.

Footnotes

Supported by DANONE Research Centre for Specialised Nutrition, Wageningen, the Netherlands and by AGIKO-stipendia 920-03-522 (to Lubbers T) and 920-03-271 (to Luyer M) from the Netherlands Organization for Health Research and Development

Peer reviewers: Piers Gatenby, MA, MD, MRCS, Department of Surgery, Royal Free and University College Medical School, London, NW3 2PF, United Kingdom; Luigi Bonavina, Professor, Department of Surgery, Policlinico San Donato, University of Milano, via Morandi 30, Milano 20097, Italy

S- Editor Wang YR L- Editor Stewart GJ E- Editor Zheng XM

References

1. Bauer AJ, Boeckxstaens GE. Mechanisms of postoperative ileus. Neurogastroenterol Motil. 2004;16 Suppl 2:54–60. [PubMed]
2. Holte K, Kehlet H. Postoperative ileus: a preventable event. Br J Surg. 2000;87:1480–1493. [PubMed]
3. Livingston EH, Passaro EP Jr. Postoperative ileus. Dig Dis Sci. 1990;35:121–132. [PubMed]
4. Story SK, Chamberlain RS. A comprehensive review of evidence-based strategies to prevent and treat postoperative ileus. Dig Surg. 2009;26:265–275. [PubMed]
5. Johnson MD, Walsh RM. Current therapies to shorten postoperative ileus. Cleve Clin J Med. 2009;76:641–648. [PubMed]
6. Kraft MD. Methylnaltrexone, a new peripherally acting mu-opioid receptor antagonist being evaluated for the treatment of postoperative ileus. Expert Opin Investig Drugs. 2008;17:1365–1377. [PubMed]
7. de Jonge WJ, van den Wijngaard RM, The FO, ter Beek ML, Bennink RJ, Tytgat GN, Buijs RM, Reitsma PH, van Deventer SJ, Boeckxstaens GE. Postoperative ileus is maintained by intestinal immune infiltrates that activate inhibitory neural pathways in mice. Gastroenterology. 2003;125:1137–1147. [PubMed]
8. Plourde V, Wong HC, Walsh JH, Raybould HE, Taché Y. CGRP antagonists and capsaicin on celiac ganglia partly prevent postoperative gastric ileus. Peptides. 1993;14:1225–1229. [PubMed]
9. Zittel TT, Lloyd KC, Rothenhöfer I, Wong H, Walsh JH, Raybould HE. Calcitonin gene-related peptide and spinal afferents partly mediate postoperative colonic ileus in the rat. Surgery. 1998;123:518–527. [PubMed]
10. Luckey A, Livingston E, Taché Y. Mechanisms and treatment of postoperative ileus. Arch Surg. 2003;138:206–214. [PubMed]
11. Holzer P, Lippe IT, Holzer-Petsche U. Inhibition of gastrointestinal transit due to surgical trauma or peritoneal irritation is reduced in capsaicin-treated rats. Gastroenterology. 1986;91:360–363. [PubMed]
12. Boeckxstaens GE, Hirsch DP, Kodde A, Moojen TM, Blackshaw A, Tytgat GN, Blommaart PJ. Activation of an adrenergic and vagally-mediated NANC pathway in surgery-induced fundic relaxation in the rat. Neurogastroenterol Motil. 1999;11:467–474. [PubMed]
13. Baig MK, Wexner SD. Postoperative ileus: a review. Dis Colon Rectum. 2004;47:516–526. [PubMed]
14. Kalff JC, Buchholz BM, Eskandari MK, Hierholzer C, Schraut WH, Simmons RL, Bauer AJ. Biphasic response to gut manipulation and temporal correlation of cellular infiltrates and muscle dysfunction in rat. Surgery. 1999;126:498–509. [PubMed]
15. Kalff JC, Carlos TM, Schraut WH, Billiar TR, Simmons RL, Bauer AJ. Surgically induced leukocytic infiltrates within the rat intestinal muscularis mediate postoperative ileus. Gastroenterology. 1999;117:378–387. [PubMed]
16. Lubbers T, Luyer MD, de Haan JJ, Hadfoune M, Buurman WA, Greve JW. Lipid-rich enteral nutrition reduces postoperative ileus in rats via activation of cholecystokinin-receptors. Ann Surg. 2009;249:481–487. [PubMed]
17. de Jonge WJ, The FO, van der Coelen D, Bennink RJ, Reitsma PH, van Deventer SJ, van den Wijngaard RM, Boeckxstaens GE. Mast cell degranulation during abdominal surgery initiates postoperative ileus in mice. Gastroenterology. 2004;127:535–545. [PubMed]
18. The FO, Bennink RJ, Ankum WM, Buist MR, Busch OR, Gouma DJ, van der Heide S, van den Wijngaard RM, de Jonge WJ, Boeckxstaens GE. Intestinal handling-induced mast cell activation and inflammation in human postoperative ileus. Gut. 2008;57:33–40. [PubMed]
19. Kalff JC, Schraut WH, Simmons RL, Bauer AJ. Surgical manipulation of the gut elicits an intestinal muscularis inflammatory response resulting in postsurgical ileus. Ann Surg. 1998;228:652–663. [PubMed]
20. Schwarz NT, Beer-Stolz D, Simmons RL, Bauer AJ. Pathogenesis of paralytic ileus: intestinal manipulation opens a transient pathway between the intestinal lumen and the leukocytic infiltrate of the jejunal muscularis. Ann Surg. 2002;235:31–40. [PubMed]
21. Kalff JC, Schraut WH, Billiar TR, Simmons RL, Bauer AJ. Role of inducible nitric oxide synthase in postoperative intestinal smooth muscle dysfunction in rodents. Gastroenterology. 2000;118:316–327. [PubMed]
22. Schwarz NT, Kalff JC, Türler A, Engel BM, Watkins SC, Billiar TR, Bauer AJ. Prostanoid production via COX-2 as a causative mechanism of rodent postoperative ileus. Gastroenterology. 2001;121:1354–1371. [PubMed]
23. Kalff JC, Türler A, Schwarz NT, Schraut WH, Lee KK, Tweardy DJ, Billiar TR, Simmons RL, Bauer AJ. Intra-abdominal activation of a local inflammatory response within the human muscularis externa during laparotomy. Ann Surg. 2003;237:301–315. [PubMed]
24. The FO, Buist MR, Lei A, Bennink RJ, Hofland J, van den Wijngaard RM, de Jonge WJ, Boeckxstaens GE. The role of mast cell stabilization in treatment of postoperative ileus: a pilot study. Am J Gastroenterol. 2009;104:2257–2266. [PubMed]
25. Kreiss C, Birder LA, Kiss S, VanBibber MM, Bauer AJ. COX-2 dependent inflammation increases spinal Fos expression during rodent postoperative ileus. Gut. 2003;52:527–534. [PMC free article] [PubMed]
26. Schmidt J, Stoffels B, Nazir A, Dehaven-Hudkins DL, Bauer AJ. Alvimopan and COX-2 inhibition reverse opioid and inflammatory components of postoperative ileus. Neurogastroenterol Motil. 2008;20:689–699. [PubMed]
27. Stoffels B, Schmidt J, Nakao A, Nazir A, Chanthaphavong RS, Bauer AJ. Role of interleukin 10 in murine postoperative ileus. Gut. 2009;58:648–660. [PubMed]
28. Kehlet H, Wilmore DW. Evidence-based surgical care and the evolution of fast-track surgery. Ann Surg. 2008;248:189–198. [PubMed]
29. Holte K, Kehlet H. Epidural anaesthesia and analgesia - effects on surgical stress responses and implications for postoperative nutrition. Clin Nutr. 2002;21:199–206. [PubMed]
30. Kehlet H, Mogensen T. Hospital stay of 2 days after open sigmoidectomy with a multimodal rehabilitation programme. Br J Surg. 1999;86:227–230. [PubMed]
31. Schmidt WK. Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist. Am J Surg. 2001;182:27S–38S. [PubMed]
32. Taguchi A, Sharma N, Saleem RM, Sessler DI, Carpenter RL, Seyedsadr M, Kurz A. Selective postoperative inhibition of gastrointestinal opioid receptors. N Engl J Med. 2001;345:935–940. [PubMed]
33. Wolff BG, Michelassi F, Gerkin TM, Techner L, Gabriel K, Du W, Wallin BA. Alvimopan, a novel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus. Ann Surg. 2004;240:728–734; discussion 734-735. [PubMed]
34. Sim R, Cheong DM, Wong KS, Lee BM, Liew QY. Prospective randomized, double-blind, placebo-controlled study of pre- and postoperative administration of a COX-2-specific inhibitor as opioid-sparing analgesia in major colorectal surgery. Colorectal Dis. 2007;9:52–60. [PubMed]
35. Holte K, Andersen J, Jakobsen DH, Kehlet H. Cyclo-oxygenase 2 inhibitors and the risk of anastomotic leakage after fast-track colonic surgery. Br J Surg. 2009;96:650–654. [PubMed]
36. Schwenk W, Haase O, Neudecker J, Müller JM. Short term benefits for laparoscopic colorectal resection. Cochrane Database Syst Rev. 2005:CD003145. [PubMed]
37. Sylla P, Kirman I, Whelan RL. Immunological advantages of advanced laparoscopy. Surg Clin North Am. 2005;85:1–18, vii. [PubMed]
38. Helman CA. Chewing gum is as effective as food in stimulating cephalic phase gastric secretion. Am J Gastroenterol. 1988;83:640–642. [PubMed]
39. Person B, Wexner SD. The management of postoperative ileus. Curr Probl Surg. 2006;43:6–65. [PubMed]
40. Lewis SJ, Andersen HK, Thomas S. Early enteral nutrition within 24 h of intestinal surgery versus later commencement of feeding: a systematic review and meta-analysis. J Gastrointest Surg. 2009;13:569–575. [PubMed]
41. Minig L, Biffi R, Zanagnolo V, Attanasio A, Beltrami C, Bocciolone L, Botteri E, Colombo N, Iodice S, Landoni F, et al. Early oral versus "traditional" postoperative feeding in gynecologic oncology patients undergoing intestinal resection: a randomized controlled trial. Ann Surg Oncol. 2009;16:1660–1668. [PubMed]
42. Spalding DR, Behranwala KA, Straker P, Thompson JN, Williamson RC. Non-occlusive small bowel necrosis in association with feeding jejunostomy after elective upper gastrointestinal surgery. Ann R Coll Surg Engl. 2009;91:477–482. [PMC free article] [PubMed]
43. Berger MM, Chiolero RL. Enteral nutrition and cardiovascular failure: from myths to clinical practice. JPEN J Parenter Enteral Nutr. 2009;33:702–709. [PubMed]
44. De Backer O, Elinck E, Blanckaert B, Leybaert L, Motterlini R, Lefebvre RA. Water-soluble CO-releasing molecules reduce the development of postoperative ileus via modulation of MAPK/HO-1 signalling and reduction of oxidative stress. Gut. 2009;58:347–356. [PubMed]
45. Moore BA, Otterbein LE, Türler A, Choi AM, Bauer AJ. Inhaled carbon monoxide suppresses the development of postoperative ileus in the murine small intestine. Gastroenterology. 2003;124:377–391. [PubMed]
46. The FO, de Jonge WJ, Bennink RJ, van den Wijngaard RM, Boeckxstaens GE. The ICAM-1 antisense oligonucleotide ISIS-3082 prevents the development of postoperative ileus in mice. Br J Pharmacol. 2005;146:252–258. [PMC free article] [PubMed]
47. Wehner S, Behrendt FF, Lyutenski BN, Lysson M, Bauer AJ, Hirner A, Kalff JC. Inhibition of macrophage function prevents intestinal inflammation and postoperative ileus in rodents. Gut. 2007;56:176–185. [PMC free article] [PubMed]
48. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, Wang H, Abumrad N, Eaton JW, Tracey KJ. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 2000;405:458–462. [PubMed]
49. van der Zanden EP, Snoek SA, Heinsbroek SE, Stanisor OI, Verseijden C, Boeckxstaens GE, Peppelenbosch MP, Greaves DR, Gordon S, De Jonge WJ. Vagus nerve activity augments intestinal macrophage phagocytosis via nicotinic acetylcholine receptor alpha4beta2. Gastroenterology. 2009;137:1029–1039, 1039.e1-e4. [PubMed]
50. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li JH, Wang H, Yang H, Ulloa L, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature. 2003;421:384–388. [PubMed]
51. O'Mahony C, van der Kleij H, Bienenstock J, Shanahan F, O'Mahony L. Loss of vagal anti-inflammatory effect: in vivo visualization and adoptive transfer. Am J Physiol Regul Integr Comp Physiol. 2009;297:R1118–R1126. [PubMed]
52. Ghia JE, Blennerhassett P, El-Sharkawy RT, Collins SM. The protective effect of the vagus nerve in a murine model of chronic relapsing colitis. Am J Physiol Gastrointest Liver Physiol. 2007;293:G711–G718. [PubMed]
53. de Jonge WJ, van der Zanden EP, The FO, Bijlsma MF, van Westerloo DJ, Bennink RJ, Berthoud HR, Uematsu S, Akira S, van den Wijngaard RM, et al. Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat Immunol. 2005;6:844–851. [PubMed]
54. The FO, Boeckxstaens GE, Snoek SA, Cash JL, Bennink R, Larosa GJ, van den Wijngaard RM, Greaves DR, de Jonge WJ. Activation of the cholinergic anti-inflammatory pathway ameliorates postoperative ileus in mice. Gastroenterology. 2007;133:1219–1228. [PubMed]
55. Huston JM, Gallowitsch-Puerta M, Ochani M, Ochani K, Yuan R, Rosas-Ballina M, Ashok M, Goldstein RS, Chavan S, Pavlov VA, et al. Transcutaneous vagus nerve stimulation reduces serum high mobility group box 1 levels and improves survival in murine sepsis. Crit Care Med. 2007;35:2762–2768. [PubMed]
56. Luyer M, Greve JW, de Haan J, Lubbers T, Buurman W. Are we finally taming inflammation? Crit Care Med. 2007;35:2003–2004. [PubMed]
57. de Haan JJ, Lubbers T, Hadfoune M, Luyer MD, Dejong CH, Buurman WA, Greve JW. Postshock intervention with high-lipid enteral nutrition reduces inflammation and tissue damage. Ann Surg. 2008;248:842–848. [PubMed]
58. Luyer MD, Buurman WA, Hadfoune M, Jacobs JA, Konstantinov SR, Dejong CH, Greve JW. Pretreatment with high-fat enteral nutrition reduces endotoxin and tumor necrosis factor-alpha and preserves gut barrier function early after hemorrhagic shock. Shock. 2004;21:65–71. [PubMed]
59. Luyer MD, Greve JW, Hadfoune M, Jacobs JA, Dejong CH, Buurman WA. Nutritional stimulation of cholecystokinin receptors inhibits inflammation via the vagus nerve. J Exp Med. 2005;202:1023–1029. [PMC free article] [PubMed]
60. Raybould HE. Mechanisms of CCK signaling from gut to brain. Curr Opin Pharmacol. 2007;7:570–574. [PMC free article] [PubMed]
61. Vásquez W, Hernández AV, Garcia-Sabrido JL. Is gum chewing useful for ileus after elective colorectal surgery? A systematic review and meta-analysis of randomized clinical trials. J Gastrointest Surg. 2009;13:649–656. [PubMed]
62. Lunding JA, Nordström LM, Haukelid AO, Gilja OH, Berstad A, Hausken T. Vagal activation by sham feeding improves gastric motility in functional dyspepsia. Neurogastroenterol Motil. 2008;20:618–624. [PubMed]
63. Fitzgerald JE, Ahmed I. Systematic review and meta-analysis of chewing-gum therapy in the reduction of postoperative paralytic ileus following gastrointestinal surgery. World J Surg. 2009;33:2557–2566. [PubMed]

Articles from World Journal of Gastroenterology are provided here courtesy of Baishideng Publishing Group Inc